J&J Has No Plans to Enter Obesity Drugs Market, CEO Says

Industry
โดย Yahoo Finance·Read original
Summary · why it matters

Johnson & Johnson has no plans to enter the booming obesity market, CEO Joaquin Duato said in an interview for an upcoming episode of The David Rubenstein Show: Peer to Peer Conversations. The company will instead focus on diseases such as cancer. The comments set J&J apart from many of its rivals that are trying to develop or acquire obesity medicines following blockbuster weight-loss drugs from Eli Lilly & Co. and Novo Nordisk.

Impact on stocks 3

Biotech & Genomic Medicine± Mixed · 3 stocks
Johnson & Johnson
JNJ
▼ NegativeDemandrelevance

CEO says J&J has no plans to enter the booming obesity drug market, missing a major growth opportunity.

Eli Lilly and Company
LLY
▲ PositiveCompetitionrelevance

J&J's decision not to enter obesity market reduces potential future competition for Eli Lilly's weight-loss drugs.

Novo Nordisk A/S
NOV
▲ PositiveCompetitionrelevance

J&J's decision not to enter obesity market reduces potential future competition for Novo Nordisk's weight-loss drugs.

© 2026 MarketDXNews